Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I Results

Peter M. Voorhees, MD, Flora Mulkey, Hani Hassoun, MD, Claudia E. Paba-Prada, MD, Yvonne A. Efebera, MD MPH, Eva Hoke, Guadalupe Aquino, Destin Carlisle, Vera Suman, Paul G. Richardson, MD

Blood (2015) 126 (23): 375.

https://doi.org/10.1182/blood.V126.23.375.375

Published: 2015

Journal Articles

CALGB 100801 (Alliance): A Phase II Multi-Center NCI Cooperative Group Study of the Addition of Azacitidine (AZA) to Reduced-Intensity Conditioning (RIC) Allogeneic Transplantation for High Risk Myelodysplasia (MDS) and Older Patients with Acute Myeloid Leukemia (AML): Results of a “test dose” Strategy to Target Busulfan Exposure

Ravi Vij, MD, Vera Hars, MS, William Blum, MD, Tsiporah B. Shore, Aaron P. Rapoport, MD, Thomas C. Shea, MD, Eva Hoke, Richard M. Stone, MD, Paula Friedman, Kouros Owzar, PhD, Steven M. Devine, MD

Blood (2014) 124 (21): 543.

https://doi.org/10.1182/blood.V124.21.543.543

Published: 2014

Journal Articles

Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance)

Meir Wetzler, MD, Dorothy Watson, B.S., Wendy Stock, MD, Kouros Owzar, PhD, Gregory Koval, B.S., Eva Hoke, John M McCarty, MD, William Blum, MD, Bayard L. Powell, MD, Guido Marcucci, MD, Clara D Bloomfield, Charles Linker, MD, Richard A. Larson, MD

Blood (2012) 120 (21): 816.

https://doi.org/10.1182/blood.V120.21.816.816

Published: 2012

Journal Articles

Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)

William Blum, MD, Ben Sanford, Rebecca B Klisovic, MD, Daniel J. DeAngelo, MD, PhD, Geoffrey Uy, MD, Bayard L. Powell, MD, Wendy Stock, MD, Maria R. Baer, M.D., Jonathan E. Kolitz, MD, Meir Wetzler, MD, Eva Hoke, Clara D. Bloomfield, MD, Susan Geyer, PhD, Guido Marcucci, MD, Richard M. Stone, MD, Richard A. Larson, MD

Blood (2012) 120 (21): 44.

https://doi.org/10.1182/blood.V120.21.44.44

Published: 2012

Journal Articles

Challenges for Conducting Clinical Trials Evaluating Maintenance Chemotherapy In Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study

William Blum, MD, Kate Donohue, PhD, Guido Marcucci, MD, Daniel J DeAngelo, MD, PhD, Geoffrey L Uy, MD, Bayard L Powell, MD, Wendy Stock, MD, Maria Baer, MD, Jonathan E Kolitz, MD, Meir Wetzler, MD, Eva Hoke, Barry K Moser, PhD, Richard A Larson, MD

Blood (2010) 116 (21): 2176.

https://doi.org/10.1182/blood.V116.21.2176.2176

Published: 2010

Journal Articles

Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002

David A. Rizzieri, MD, Jeffrey L Johnson, John C. Byrd, MD, Gerard Lozanski, MD, Bayard L. Powell, MD, Thomas C. Shea, MD, Sreenivasa Nattom, Eva Hoke, Bruce D. Cheson, MD, Richard Larson, M.D.

Blood (2010) 116 (21): 858.

https://doi.org/10.1182/blood.V116.21.858.858

Published: 2010

Journal Articles

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

Jonathan E. Kolitz, Stephen L. George, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. DeAngelo, Thomas C. Shea, Wendy Stock, Maria R. Baer, Vera Hars, Kati Maharry, Eva Hoke, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson, for the Cancer and Leukemia Group B

Blood (2010) 116 (9): 1413–1421.

https://doi.org/10.1182/blood-2009-07-229492

Published: 2010

Journal Articles

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101.

Thomas S Lin, MD, PhD, Kathleen A Donohue, John C. Byrd, MD, Margaret S Lucas, Eva Hoke, Elizabeth M Bengtson, MD, James N Atkins, MD, Brian K Link, MD, Kanti R Rai, MD, Richard A Larson, MD

Blood (2009) 114 (22): 210.

https://doi.org/10.1182/blood.V114.22.210.210

Published: 2009

Journal Articles

Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102).

Wendy Stock, MD, Ben Sanford, M.A., Gerard Lozanski, M.D., Ravi Vij, MD, John C. Byrd, Bayard L. Powell, MD, Meir Wetzler, MD, Dorie Sher, B.S., Colin Edwards, Ph.D., Michael Kelly, B.S., Sue Richards, Ph.D, Crystal Sung, PhD, Greg Malnassy, B.S., Eva Hoke, BA, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2009) 114 (22): 838.

https://doi.org/10.1182/blood.V114.22.838.838

Published: 2009

Journal Articles

Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808.

Jonathan E. Kolitz, Vera Hars, Daniel J. DeAngelo, Steven L. Allen, Thomas C. Shea, Ravi Vij, Eva Hoke, Clara D. Bloomfield, Michael A. Caligiuri, Stephen L. George, Richard A. Larson

Blood (2007) 110 (11): 157.

https://doi.org/10.1182/blood.V110.11.157.157

Published: 2007

Journal Articles

Feasibility of Administering Oblimersen (G3139; Genasense) with Imatinib Mesylate in Patients with Imatinib Resistant Chronic Myeloid Leukemia (CML) - Cancer and Leukemia Group B Study 10107.

Meir Wetzler, MD, Daohai Yu, PhD, Olatoyosi Odenike, MD, Eric J. Feldman, MD, David D. Hurd, MD, Eva Hoke, Vera Hars, Richard A. Larson, MD

Blood (2005) 106 (11): 1097.

https://doi.org/10.1182/blood.V106.11.1097.1097

Published: 2005

Journal Articles

A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808.

Jonathan E. Kolitz, Stephen L. George, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. De Angelo, Thomas Shea, Wendy Stock, Vera Hars, Eva Hoke, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson

Blood (2005) 106 (11): 407.

https://doi.org/10.1182/blood.V106.11.407.407

Published: 2005

Journal Articles

Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).

Wendy Stock, MD, Daohai Yu, PhD, Ben Sanford, MS, Gerard Lozanski, Ph.D, Spero Cataland, MD, Ravi Vij, MD, John Byrd, MD, Bayard Powell, MD, Meir Wetzler, MD, Maher Albitar, MD, Dorie Sher, BS, Colin Edwards, MS, Eva Hoke, BS, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2005) 106 (11): 145.

https://doi.org/10.1182/blood.V106.11.145.145

Published: 2005

Journal Articles

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)

John C. Byrd, Bercedis L. Peterson, Vicki A. Morrison, Kathleen Park, Robert Jacobson, Eva Hoke, James W. Vardiman, Kanti Rai, Charles A. Schiffer, Richard A. Larson

Blood (2003) 101 (1): 6–14.

https://doi.org/10.1182/blood-2002-04-1258

Published: 2003

NARROW

Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I Results

Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance)

Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)

Challenges for Conducting Clinical Trials Evaluating Maintenance Chemotherapy In Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study

Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102).

Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808.

Feasibility of Administering Oblimersen (G3139; Genasense) with Imatinib Mesylate in Patients with Imatinib Resistant Chronic Myeloid Leukemia (CML) - Cancer and Leukemia Group B Study 10107.

A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808.

Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only